Elamipretide vs BYM338
Head-to-head comparison of Elamipretide (Elamipretide (MTP-131, SS-31)) and BYM338 (Bimagrumab (BYM338)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Elamipretide | BYM338 |
|---|---|---|
| Category | Muscle & Performance | Muscle & Performance |
| Full Name | Elamipretide (MTP-131, SS-31) | Bimagrumab (BYM338) |
| Molecular Weight | 639.8 Da | ~148 kDa |
| Half-Life | 1-4 hours | ~2-3 weeks |
| Amino Acids | 4 | N/A |
| Typical Dose | 0.01-0.25 mg/kg/day | 10-30 mg/kg IV in trials |
| Route | Subcutaneous/Intravenous | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 120 | 140 |
| Research Status | Clinical | Clinical |
Elamipretide Benefits
- ✓mitochondrial protection
- ✓reduced oxidative stress
- ✓improved fatigue resistance
- ✓may support exercise tolerance
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
Elamipretide Dosing
0.01-0.25 mg/kg/day SC (clinical research)|daily dosing in trials|alternative IV protocols in some studies
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
Elamipretide Side Effects
- ⚠nausea
- ⚠injection-site reactions
- ⚠diarrhea
- ⚠headache
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Research Overview
Elamipretide
Clinical and translational studies show elamipretide can improve mitochondrial function and some functional endpoints in mitochondrial disorders. Skeletal muscle research suggests benefits are driven by energy metabolism rather than direct muscle-building effects.
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.